The S100A9 inhibitor tasquinimod already demonstrated both efficacy and a favorable toxicity profile in castrate-resistant prostate cancer (NCT01732549, NCT01234311) and might offer an alternative and safer approach to disturb the cancer cell metabolism. The gene discussed is S100A9; the disease is prostate carcinoma.